NASDAQ:EGRX
Eagle Pharmaceuticals Stock News
$5.24
+0.230 (+4.59%)
At Close: Mar 28, 2024
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
11:19am, Monday, 27'th Nov 2023
Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
11:17am, Friday, 10'th Nov 2023
The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
Eagle Delays Third Quarter 2023 Results and Conference Call
07:30am, Thursday, 09'th Nov 2023
WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
08:30am, Wednesday, 08'th Nov 2023
WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 20
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
09:46am, Friday, 29'th Sep 2023
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
04:05pm, Tuesday, 19'th Sep 2023
WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence factors to reduce damage and mitigate disease ---- The
-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam -- Abstract compares relative effects on cognitive function foll
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
04:05pm, Tuesday, 22'nd Aug 2023
WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and B
Eagle Pharmaceuticals (EGRX) Tops Q2 Earnings and Revenue Estimates
09:55am, Tuesday, 08'th Aug 2023
Eagle Pharmaceuticals (EGRX) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.56 per share a year ago.
Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
06:50am, Tuesday, 01'st Aug 2023
WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2
Eagle Pharmaceuticals gets FDA designations that will grant it extra exclusivity for bacterial pneumonia treatment
07:05am, Wednesday, 14'th Jun 2023
Eagle Pharmaceutics Inc. EGRX said Wednesday it has won Food and Drug Administration Qualified Infectious Disease Product (QDIP) and Fast-Track Designation for CAL02, a treatment for severe community-
Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023
04:30pm, Thursday, 27'th Apr 2023
WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
12:05pm, Monday, 13'th Mar 2023 Zacks Investment Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock